|
| 重组人粒细胞集落刺激因子不同用药时机对化疗后中性粒细胞水平的影响分析 |
|
| |
| DOI： |
| 中文关键词: 重组人粒细胞集落刺激因子 中性粒细胞减少 用药时机 回顾性分析 |
| 英文关键词:Recombinant human granulocyte colony stimulating factor Neutropenia Treatment opportunities Retrospective analysis |
| 基金项目:成都药学会赞邦药学科研基金项目（编号：20161209） |
|
| 摘要点击次数: 1605 |
| 全文下载次数: 1662 |
| 中文摘要: |
| 摘 要 目的：探讨重组人粒细胞集落刺激因子（rhG CSF）不同用药时机对化疗后中性粒细胞水平的影响。 方法：采用回顾性分析方法，收集我院2017～2018年147例宫颈癌化疗患者，所有患者在化疗前均合并Ⅰ度中性粒细胞减少，根据rhG CSF不同的用药时机分为3组：A组(48例)化疗前24～48 h内给予rhG CSF；B组（49例）化疗前24 h内给予rhG CSF；C组（50例）化疗前不给予rhG CSF，化疗后24～48 h内给予rhG CSF。对比分析化疗后21 d内3组患者中性粒细胞减少及中性粒细胞缺乏伴发热（FN）事件的发生情况。 结果：3组患者发生中性粒细胞减少的程度差异有统计学意义（P＜0.05）。两两比较，A组与B组、A组与C组比较差异均无统计学意义（P＞0.05），而B组与C组比较差异有统计学意义（P＜0.05）。B组发生5例FN事件，发生率为10.2%，明显高于A组（0例）和C组（0例）（P＜0.05）。 结论：化疗前合并Ⅰ度中性粒细胞减少的患者，在化疗前24～48 h使用rhG CSF，或化疗前不使用rhG CSF，化疗后24～48 h再使用rhG CSF，发生中性粒细胞减少及FN事件明显少于化疗前24 h内使用rhG CSF。 |
| 英文摘要: |
| ABSTRACT Objective:To investigate impact on neutrophil counts of patients after chemotherapy between different treatment opportunities of recombinant human granulocyte colony stimulating factor. Methods:147 cervical cancer patients undergoing chemotherapy from January 2017 to December 2018 were collected. All patients with I° neutropenia before chemotherapy were divided into three groups: 48 patients (group A) were treated with rhG CSF 24 48 h before chemotherapy, 49 patients (group B) were treated with rhG CSF within 24 h before chemotherapy, 50 patients (group C) were treated with rhG CSF 24 48 h after chemotherapy. The incidence of neutropenia and febrile neutropenia were compared and analyzed within 21 days after chemotherapy. Results:There were statistically significant differences in the degree of neutropenia among the 3 groups (P<0.05). There were no statistically significant differences between group A and B, even A and C (P＞0.05), but there was statistically significant difference between group B and C. There were 5 febrile neutropenia cases, the incidence rate was 10.2%, it was significantly higher than group A (0 cases) and C (0 cases) (P<0.05). Conclusion:For the patients with Ⅰ° neutropenia before chemotherapy, rhG CSF was given 24 48 h before chemotherapy, or no use rhG CSF before chemotherapy, given rhG CSF 24 48 h after chemotherapy again. There were few neutropenia and febrile neutropenia cases significantly less than the treating with rhG CSF 24 h before chemotherapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
